Unknown

Dataset Information

0

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).


ABSTRACT: Trop-2 is a novel target for ADC therapy because of its high expression by many solid cancers. The rational development of IMMU-132 represents a paradigm shift as an ADC that binds a well-known moderately-cytotoxic drug, SN-38, to the anti-Trop-2 antibody. In vitro and in vivo studies show enhanced efficacy, while there is a gradual release of SN-38 that contributes to the overall effect. IMMU-132 is most efficacious at a high drug:antibody ratio (DAR) of 7.6:1, which does not affect binding and pharmacokinetics. It targets up to 136-fold more SN-38 to a human cancer xenograft than irinotecan, SN-38's prodrug. IMMU-132 delivers SN-38 in its most active, non-glucuronidated form, which may explain the lower frequency of severe diarrhea than with irinotecan. Thus, this ADC, carrying a moderately-toxic drug targeting Trop-2 represents a novel cancer therapeutic that is showing promising activity in patients with several metastatic cancer types, including triple-negative breast cancer, non-small-cell and small-cell lung cancers.

SUBMITTER: Goldenberg DM 

PROVIDER: S-EPMC4673178 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).

Goldenberg David M DM   Cardillo Thomas M TM   Govindan Serengulam V SV   Rossi Edmund A EA   Sharkey Robert M RM  

Oncotarget 20150901 26


Trop-2 is a novel target for ADC therapy because of its high expression by many solid cancers. The rational development of IMMU-132 represents a paradigm shift as an ADC that binds a well-known moderately-cytotoxic drug, SN-38, to the anti-Trop-2 antibody. In vitro and in vivo studies show enhanced efficacy, while there is a gradual release of SN-38 that contributes to the overall effect. IMMU-132 is most efficacious at a high drug:antibody ratio (DAR) of 7.6:1, which does not affect binding and  ...[more]

Similar Datasets

| S-EPMC7075468 | biostudies-literature
| S-EPMC5559902 | biostudies-literature
| S-EPMC7007291 | biostudies-literature
| S-EPMC6030029 | biostudies-literature
| S-EPMC7303962 | biostudies-literature
| S-EPMC4558321 | biostudies-literature
| S-EPMC6976591 | biostudies-literature
| S-EPMC6748572 | biostudies-literature
| S-EPMC9812893 | biostudies-literature